IRONWOOD PHARMACEUTICALS INC (IRWD) Form 8-K — Oct 16, 2026

$IRWDForm 8-KItems 5.02, 9.01Filed Oct 16, 2026, 7:30 AM ET0001104659-26-116423Original filing

Ironwood Pharmaceuticals' board appointed Tammi Gaskins, currently Chief Commercial Officer, as CEO and director effective January 1, 2027, succeeding Tom McCourt, who retires December 31, 2026 after 17 years with the company and five as CEO. McCourt will remain on the board and serve as a consultant at an anticipated $10,000 per month. Gaskins receives a $775,000 base salary, a 75% bonus target, and RSU and PSU grants with target values of approximately $2 million each.

Key figures

Ceo base salary: 775000
Psu target value: 2000000
Rsu target value: 2000000
Ceo bonus target pct: 75
Transition effective date: January 1, 2027
Mccourt consulting fee monthly: 10000

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.